Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects-Reference-Cited by-同舟云学术

Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects

Published:2020-01 Issue:1 Volume:14 Page:77-87
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Taskinen Marja-Riitta,Björnson Elias,Andersson Linda,Kahri Juhani,Porthan Kimmo,Matikainen Niina,Söderlund Sanni,Pietiläinen Kirsi,Hakkarainen Antti,Lundbom Nina,Nilsson Ralf,Ståhlman Marcus,Adiels Martin,Parini Paolo,Packard Chris,Borén Jan

Funder

Amgen for an investigator-initiated research project

Swedish Heart-Lung Foundation

Swedish Diabetes Foundation

Swedish Research Council and Sahlgrenska University Hospital

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference51 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

2. Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer;Ginsberg;Ann Intern Med,1997

3. Hypertriglyceridemia as a cardiovascular risk factor;Austin;Am J Cardiol,1998

4. Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence;Miller;Eur Heart J,1998

5. Postprandial lipemia and cardiovascular disease;Hyson;Curr Atheroscler Rep,2003

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A promising therapy for fatty liver disease: PCSK9 inhibitors;Phytomedicine;2024-06

2. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

3. Eradicating Atherosclerotic Events by Targeting Early Subclinical Disease: It Is Time to Retire the Therapeutic Paradigm of Too Much, Too Late;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-01

4. Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial;Journal of Clinical Lipidology;2023-09

5. PCSK9 in extrahepatic tissues: What can we expect from its inhibition?;European Atherosclerosis Journal;2023-08-31